LIXTE BIOTECHNOLOGY HOLDINGS, INC. Income Statement
LIXT|4 years of annual SEC 10-K data (FY2011-FY2015)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported $200,000 in revenue and $3M in net loss for FY2015. Its profit margin was -1383.1% in FY2015.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -11.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2015 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|
| Revenue | $200.0K | $0 | $0 | $0 |
| SG&A Expense | $1.3M | $1.1M | $533.4K | $436.1K |
| R&D Expense | $1.1M | $1.0M | $1.3M | $445.5K |
| Operating Income | -$2.4M | -$2.1M | -$1.9M | -$881.7K |
| Interest Expense | - | $0 | $0 | $0 |
| Net Income | -$2.8M | -$16.1K | -$16.1K | -$16.1K |
| EPS (Diluted) | -$0.06 | -$0.09 | -$0.06 | -$0.03 |
| Shares Outstanding | 45.5M | 25.0M | 25.0M | 35.1M |
| Operating Margin | -1201.6% | - | - | - |
| Profit Margin | -1383.1% | - | - | - |